Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) has been given a consensus recommendation of “Buy” by the six research firms that are covering the stock, Marketbeat.com reports. Six research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have covered the stock in the last year […]
Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a report issued on Friday morning, Benzinga reports. They currently have a $8.00 price objective on the stock. ELEV has been the topic of several other reports. JMP Securities restated a market outperform rating and set a $7.00 target price […]
Comparing Aura Biosciences (NASDAQ:AURA) & Elevation Oncology (NASDAQ:ELEV) theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.
Wedbush restated their outperform rating on shares of Elevation Oncology (NASDAQ:ELEV – Free Report) in a research report sent to investors on Friday morning, Benzinga reports. Wedbush currently has a $8.00 price objective on the stock. A number of other analysts have also issued reports on ELEV. HC Wainwright reiterated a buy rating and set […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Free Report) was the recipient of a significant increase in short interest during the month of March. As of March 15th, there was short interest totalling 4,630,000 shares, an increase of 28.3% from the February 29th total of 3,610,000 shares. Approximately 11.6% of the company’s shares are sold short. […]